The 7 most recent market catalysts affecting $NKTR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 25, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
This filing indicates that BTIG analyst Julian Harrison has reaffirmed their 'Buy' rating on Nektar Therapeutics (NKTR) and maintained a $178 price target. This is a routine analys…
Sep 16, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
This 8-K filing discloses that BTIG analyst Julian Harrison has reiterated a 'Buy' rating for Nektar Therapeutics and maintained a $178 price target. This action signals continued …
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
This filing indicates that BTIG analyst Julian Harrison has reaffirmed their 'Buy' rating and $178 price target for Nektar Therapeutics. This is a reiteration, meaning the analyst'…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 65
Nektar Therapeutics Enters Quiet Period Beginning September 8 Until Public Announcement Of Data From 24-Week Off Treatment Follow-Up Period Of Phase 2b REZOLVE-AA Study Of Rezpegaldesleukin In Patients With Alopecia Areata
Nektar Therapeutics has entered a quiet period, effective September 8th, until the public announcement of data from the 24-week off-treatment follow-up period of its Phase 2b REZOL…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 85
Nektar Therapeutics Announces Publication Of Peer-Reviewed Data From 16-Week Induction Period Of REZOLVE-AD, Phase 2b Study Evaluating Rezpegaldesleukin In Adults With Atopic Dermatitis
Nektar Therapeutics has published peer-reviewed data from the 16-week induction period of its Phase 2b REZOLVE-AD study for rezpegaldesleukin in atopic dermatitis. The key takeaway…
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 55
JP Morgan Reinstates Neutral on Nektar Therapeutics, Announces $65 Price Target
JP Morgan's reinstatement of coverage on Nektar Therapeutics with a 'Neutral' rating and a $65 price target provides a fresh perspective from a major investment bank. This action i…
Jul 22, 2026
Corporate Catalyst
Neutral
Impact 65
Canaccord Genuity Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $153
Canaccord Genuity's initiation of coverage on Nektar Therapeutics with a 'Buy' rating and a $153 price target is a positive development for the company. Analyst coverage, especiall…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.